On Jun 29, 2018 Intersect Ent Inc (NASDAQ:XENT) Sellers Rose Their Shorts By 6.78%

June 29, 2018 - By Charla Downs

Intersect ENT, Inc. (NASDAQ:XENT) Corporate Logo

It was showed an increase on Intersect Ent Inc (NASDAQ:XENT)’s short interest with 6.78%. It was published in June by FINRA the 305,400 short interest on XENT. That’s 6.78% up from 286,000 shares. With Average volume 193,600, XENT’s previous position will take 2 days to recover. Intersect Ent Inc’s short interest float is 1.14%.

The stock decreased 1.19% or $0.45 during the last trading session, hitting $37.45.Intersect ENT, Inc. has volume of 87,979 shares. Since June 29, 2017 XENT has risen 64.79% and is uptrending. The stock outperformed the S&P 500 by 52.22%.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States.The firm is worth $1.13 billion. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.Last it reported negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

Intersect ENT, Inc. (NASDAQ:XENT) Ratings Coverage

A total of 3 analysts rate Intersect ENT (NASDAQ:XENT) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:XENT) has 4 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Tuesday, January 2 JP Morgan upgraded the shares of XENT in report to “Overweight” rating. On Monday, May 7 the company was maintained by Canaccord Genuity. On Thursday, January 4 the stock has “Buy” rating by Canaccord Genuity. On Wednesday, May 2 J.P. Morgan maintained Intersect ENT, Inc. (NASDAQ:XENT) rating. J.P. Morgan has “Buy” rating and $4800 target.

Another two news for Intersect ENT, Inc. (NASDAQ:XENT) were recently posted by: Prnewswire.com on June 18, 2018 with title “Faruqi & Faruqi, LLP is Investigating Intersect ENT, Inc. (XENT) on Behalf of its Shareholders”. The other Fool.com‘s article was titled “3 Top Healthcare Stocks to Buy Right Now” and posted on June 01, 2018.

Intersect ENT, Inc. (NASDAQ:XENT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.